Mestag Therapeutics
New therapies for inflammatory disease and cancer by targeting fibroblast immunology
New therapies for inflammatory disease and cancer by targeting fibroblast immunology
Mestag Therapeutics is a biotechnology startup that aims to revolutionize the treatment of inflammatory disease and cancer by focusing on fibroblast-immune interactions. Their unique understanding of fibroblast immunology has paved the way for the development of innovative new treatments. The company boasts a pipeline of first-in-class antibody programs and targets for new treatments. Founded in 2020 and headquartered in the United Kingdom, Mestag has garnered significant attention in the investment space. In a recent funding round on 20 April 2021, the company secured a noteworthy $11.00M investment from prominent investors including SV Health Investors and Johnson & Johnson Innovation – JJDC. With a world-class founder, a committed leadership team, and substantial financial backing, Mestag offers an enticing opportunity for investors looking to tap into the potential of cutting-edge biotechnology in the healthcare and wellness sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $11.00M | 2 |
|
20 Apr 2021 |
No recent news or press coverage available for Mestag Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
